Medtronic announced new results from Symplicity HTN-1, the longest running clinical trial investigating the safety and efficacy of renal denervation. These data showed patients who received renal denervation treatment with the Symplicity system experienced a mean blood pressure reduction of -29/-14 mm Hg at 24 months. These data expand the total number of patients to nearly two times the number previously reported at 24 months from this clinical trial. The safety of renal denervation with the Symplicity system was also maintained at 24 months. The expanded two year cohort data were presented for the first time today at the 24th Annual Transcatheter Cardiovascular Therapeutics, or TCT, scientific symposium, sponsored by the Cardiovascular Research Foundation. The Symplicity system is only available for investigational use in the U.S.